4162 智擎 - 😊 Phase 1 study of nanoliposo...

\ud83d\ude0a Phase 1 study of nanoliposo

OX · 2023-01-10T11:42:23Z

\ud83d\ude0a Phase 1 study of nanoliposomal irinotecan in combination with trifluridine/tipiracil in refractory solid tumors. 納米脂質體伊立替康(Nal-IRI, ONIVYDE®)聯合 trifluridine/tipiracil 治療難治性實體瘤的 1 期研究 Journal of Clinical Oncology Vol 40, Issue 4_suppl. 2022 結論： The MTD of Nal-IRI in combination with TAS-102 every 2 weeks is 80/30 mg/m2, which is also the RP2D for expansion study. The clinical benefit was observed in pts at different dose levels. The expansion portion of the study is still ongoing and pts will be followed until disease progression or consent withdrawal. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.4_suppl.660